mindtalks brand growth: Orthostatic Hypotension Drugs Market – 42% of Growth to Originate from North America |Evolving Opportunities with Amneal Pharmaceuticals Inc. & Apotex Inc| Technavio – Yahoo Finance – picked by mindtalks

NEW YORK, May 10, 2022 /PRNewswire/ — The Orthostatic Hypotension Drugs Market offers a comprehensive analysis of new product launches, the latest trends, drivers, and challenges. The orthostatic hypotension drugs market value is set to grow by USD 571.76 million from 2021 to 2026, progressing at a CAGR of 9.06% as per the latest market report by Technavio. 42% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for the orthostatic hypotension drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW. The high per capita pharmaceutical expenditure will facilitate the orthostatic hypotension drugs market growth in North America over the forecast period.

Technavio has announced its latest market research report titled Orthostatic Hypotension Drugs Market by Product and Geography - Forecast and Analysis 2022-2026

Technavio has announced its latest market research report titled Orthostatic Hypotension Drugs Market by Product and Geography – Forecast and Analysis 2022-2026

For more insights on the market share of various regions – Download a sample now!

Market Dynamics

The market is driven by factors such as the increasing prevalence of oh in the geriatric population, the increasing prevalence of chronic diseases associated with a high risk of OH, and the high market growth opportunities for oh drugs in emerging countries. However, the low diagnosis rate of OH is hindering market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Company Profiles

The orthostatic hypotension drugs market is fragmented and the vendors are deploying growth strategies such as expanding their product portfolios by investing in R and D to compete in the market. The orthostatic hypotension drugs market report includes information on the product launches, sustainability, and prospects of leading vendors including Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc.

Few companies with key offerings

  • Amneal Pharmaceuticals Inc.-The company offers orthostatic hypotension drugs that have the strength of 0.1 mg and are available in the dosage form of tablets, under the brand name of Fludrocortisone Acetate USP.

  • Apotex Inc. –The company offers orthostatic hypotension drugs that are available in dosage form of 2.5 mg, 5 mg, and 10 mg tablets for oral administration with Midodrine hydrochloride as its active ingredient, under the brand name Midodrine. hydrochloride.

  • Avadel Pharmaceuticals plc –The company offers orthostatic hypotension drugs that are indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia, under the brand name Akovaz.

  • Baxter International Inc. –The company offers orthostatic hypotension drugs that are indicated to raise blood pressure in adult patients with severe, acute hypotension, under the brand name Norepinephrine.

  • Endo Inc –The company offers orthostatic hypotension drugs that are used for primary and secondary adrenocortical insufficiency in Addison disease and for the treatment of salt-losing adrenogenital syndrome, under the brand name Florinef.

  • To know about the offerings of each major vendor – Download a sample now!

Competitive Analysis

The report includes the competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Don’t wait, Make a strategic approach & boost your business goals with our Orthostatic Hypotension Drugs Market Forecast Report – Buy Now!

Segmentation Analysis

  • By Product, the market is classified as midodrine, northern (droxidopa), fludrocortisone, and other drugs.

  • By Geography, the market is classified as North America, Europe, Asia, and the Rest of the World (ROW).

To know about the contribution of each segment – Download a sample now!

Related Reports:

  • The topical drugs market share is predicted to value at USD 70.95 billion by 2026, at an accelerating CAGR of 7.73%. Download a sample now!

  • The rheumatoid arthritis drugs market share is expected to reach an estimated USD 14.90 billion by 2026 at an accelerating CAGR of 7.73%. Download a sample now!

Orthostatic Hypotension Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.06%

Market growth 2022-2026

USD 571.76 million

Market structure

Fragmented

YoY growth (%)

6.44

Performing market contribution

North America at 42%

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Content

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition

  • 3.3 Market size 2021

4 Five Forces Analysis

  • 4.1 Five forces summary

  • 4.6 Threat of rivalry

  • 4.7 Market condition

5 Market Segmentation by Product

  • 5.1 Market segments

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers

  • 8.2 Market challenges

  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview

  • 9.2 Vendor landscape

  • 9.3 Landscape disruption

  • 9.4 Industry risks

10 Vendor Analysis

  • 10.1 Vendors covered

  • 10.4 Apotex Inc.

  • 10.8 H. Lundbeck AS

  • 10.9 Novartis AG

  • 10.10 Pfizer Inc.

  • 10.12 Viatris Inc.

11 Appendix

  • 11.1 Scope of the report

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/orthostatic-hypotension-drugs-market—42-of-growth-to-originate-from-north-america-evolving-opportunities-with-amneal-pharmaceuticals-inc–apotex-inc-technavio-301542534.html

SOURCE Technavio

Source: finance.yahoo.com

 

mindtalks.ai ™ – mindtalks is a patented non-intrusive survey methodology that delivers immediate insights through non-intrusively posted questions on content websites (web publishers), mobile applications, and advertisements (ads). The conversation is just beginning !, click here to sign-up and connect with other mindtalkers who contribute unique insights and quality answers on this ai-picked talk.

Related Articles

Responses

Your email address will not be published. Required fields are marked *